This study uses A-share listed companies on the Shanghai and Shenzhen stock exchanges from 2011 to 2024 as a sample to investigate the impact of corporate ESG performance on equity financing costs. The results indicate that improved ESG performance significantly reduces the cost of equity financing, and this conclusion remains robust after variable replacements and the exclusion of samples from the COVID-19 period. Commercial credit and earnings per share serve as transmission mechanisms between ESG performance and equity financing costs, while the role of stock liquidity follows a specific logic. Heterogeneity analysis shows that the effect is more pronounced in non-polluting firms, firms outside the eastern region, non-asset-intensive firms, and firms whose executives have a financial background.

Show more

This paper looks at how systematic risk—measured through beta coefficients—behaves differently depending on whether we use daily or monthly return data. We pick nine major industry sectors and run standard market model regressions at both frequencies over a three-year window (March 2017 to March 2020, using S&P 500 as the benchmark). What we find is pretty striking: for most sectors, the sign of the average beta actually flips between daily and monthly estimates. Daily betas tend to be noisy and jump around a lot, while monthly ones give much smoother trajectories. These results suggest that anyone relying on just one frequency for risk assessment might be getting an incomplete—or even misleading—picture. We also argue that simple OLS-based approaches, rather than fancy machine learning models, work quite well here precisely because complex models tend to overfit the short-term noise.

Show more

Green finance is a pivotal market-oriented instrument for coordinating economic growth with ecological sustainability. Against the backdrop of China's Green Finance Reform and Innovation Pilot Zone (GFRIPZ) policy, this paper utilizes this policy implemented in 2017 as a quasi-natural experiment to investigate its impact on corporate environmental investment. Based on data from Shanghai and Shenzhen A-share listed companies from 2011 to 2024, this study conducts an empirical test using the Difference-in-Differences (DID) model. The results indicate that the pilot policy significantly promotes corporate environmental investment. Mechanism analysis demonstrates that the policy drives investment through two main channels: first, by increasing government environmental subsidies to provide fiscal incentives; and second, by strengthening regional environmental regulation intensity to exert external pressure. Furthermore, heterogeneity analysis reveals that the promoting effect of the pilot policy on environmental investment is more pronounced for non-state-owned enterprises and non-heavily polluting firms. This paper provides empirical evidence for assessing the micro-level effectiveness of green finance policies and offers theoretical support for optimizing resource allocation and driving a comprehensive green economic transformation.

Show more

Based on my more than four years of work experience in the pharmaceutical industry, I once regarded "compliance" as an external constraint rather than a core competitiveness. In the era of short videos, numerous peers have released content that skirts regulatory rules to drive traffic and achieve considerable profits. This situation made me somewhat eager for quick success and instant benefits, as I was overly eager to achieve better results and more career development opportunities. Consequently, pharmaceutical supervision laws and regulations such as Decree No.24 once became a straitjacket that hindered me from creating outstanding and influential promotional content. Later, when contemplating entrepreneurship, I realized this issue—what was a constraint for me could also be an opportunity from another perspective. Upon reflection, the particularity of the pharmaceutical industry (e.g., the stringent restrictions on publicity stipulated in the Advertising Law and the Drug Administration Law) is precisely the cornerstone for building user trust. Some practitioners have resorted to edge-ball practices, leading to market chaos and a decline in consumer trust. During a business trip for market research last year, I found that traditional pharmaceutical marketing models (e.g., offline promotion) are experiencing diminishing efficiency. These models have failed to fully embrace the digital trend, resulting in the loss of early traffic dividends. The number of in-store purchasers has decreased, and more young people choose to buy pharmaceutical products through online food delivery platforms.

Show more